Body Mass Index and response to rituximab in rheumatoid arthritis

Joint Bone Spine

Volumn 82, Issue 6, 2015, Pages 432-436

  Ottaviani, Sébastien ^a,b   Gardette, Anaïs ^a,b   Roy, Carine ^a,b   Tubach, Florence ^a,b   Gill, Ghislaine ^a,b   Palazzo, Elisabeth ^a,b   Meyer, Olivier ^a,b   Dieudé, Philippe ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Adipose tissue; Obesity; Rheumatoid arthritis; Rituximab

Indexed keywords

C REACTIVE PROTEIN; CETIRIZINE; CORTICOSTEROID; METHYLPREDNISOLONE; RITUXIMAB; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DAS28; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PREMEDICATION; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VISUAL ANALOG SCALE; ARTHRITIS, RHEUMATOID; COMPLICATION; MIDDLE AGED;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; FEMALE; HUMANS; MALE; MIDDLE AGED; OVERWEIGHT; RETROSPECTIVE STUDIES; RITUXIMAB;

EID: 84936984834     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.02.011     Document Type: Article

References (35)

1. WHO Obesity: preventing and managing the global epidemic 2000, Technical Report Series 894.
2. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783.
3. Muller-Ladner U., Neumann E. Rheumatoid arthritis: the multifaceted role of adiponectin in inflammatory joint disease. Nat Rev Rheumatol 2009, 5:659-660.
4. Stavropoulos-Kalinoglou A., Metsios G.S., Koutedakis Y., et al. Obesity in rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:450-462.
5. Naranjo A., Sokka T., Descalzo M.A., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008, 10:R30.
6. Armstrong D.J., McCausland E.M., Quinn A.D., et al. Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:782. [author reply 782-3].
7. Voigt L.F., Koepsell T.D., Nelson J.L., et al. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 1994, 5:525-532.
8. Symmons D.P., Bankhead C.R., Harrison B.J., et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997, 40:1955-1961.
9. Westhoff G., Rau R., Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007, 56:3575-3582.
10. van der Helm-van Mil A.H., van der Kooij S.M., Allaart C.F., et al. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008, 67:769-774.
11. Kaufmann J., Kielstein V., Kilian S., et al. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 2003, 30:2350-2355.
12. Roubenoff R., Roubenoff R.A., Ward L.M., et al. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992, 19:1505-1510.
13. Klaasen R., Wijbrandts C.A., Gerlag D.M., et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011, 63:359-364.
14. Gremese E., Carletto A., Padovan M., et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 2013, 65:94-100.
15. Heimans L., van den Broek M., le Cessie S., et al. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013, 65:1235-1242.
16. di Minno M.N., Peluso R., Iervolino S., et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013, 65:141-147.
17. Eder L., Thavaneswaran A., Chandran V., et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 2014, 74:813-817.
18. Ottaviani S., Allanore Y., Tubach F., et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 2012, 14:R115.
19. Gremese E., Bernardi S., Bonazza S., et al. Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatology (Oxford) 2014, 53:875-881.
20. Sellam J., Hendel-Chavez H., Rouanet S., et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011, 63:933-938.
21. Solau-Gervais E., Prudhomme C., Philippe P., et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 2012, 79:281-284.
22. Soliman M.M., Hyrich K.L., Lunt M., et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012, 39:240-246.
23. Gardette A., Ottaviani S., Tubach F., et al. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine 2014, 81:416-420.
24. Aletaha D., Neogi T., Silman A.J., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
25. Smolen J.S., Landewe R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
26. Buch M.H., Smolen J.S., Betteridge N., et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:909-920.
27. van Gestel A.M., Haagsma C.J., van Riel P.L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850.
28. Hanley M.J., Abernethy D.R., Greenblatt D.J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010, 49:71-87.
29. de Rooy D.P., van der Linden M.P., Knevel R., et al. Predicting arthritis outcomes - what can be learned from the Leiden Early Arthritis Clinic?. Rheumatology (Oxford) 2011, 50:93-100.
30. Aparicio V.A., Ortega F.B., Carbonell-Baeza A., et al. Fibromyalgia's key symptoms in normal-weight, overweight, and obese female patients. Pain Manag Nurs 2013, 14:268-276.
31. Neumann E., Frommer K., Vasile M., et al. Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?. Arthritis Rheum 2011, 63:1159-1169.
32. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25:4-7.
33. Stavropoulos-Kalinoglou A., Metsios G.S., Panoulas V.F., et al. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 2012, 14:R160.
34. Coll A.P., Thomas S., Mufti G.J. Rituximab therapy for the type B syndrome of severe insulin resistance. N Engl J Med 2004, 350:310-311.
35. Camus V., Lanic H., Kraut J., et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol 2014, 93:9-18.